͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | We are delighted to announce the next phase of the International Alliance for Cancer Early Detection (ACED), welcoming Dana-Farber Cancer Institute (DFCI) and the German Cancer Research Center (DKFZ) to our growing research community.
ACED is unique in uniting world-leading researchers from institutions around the globe to tackle the most pressing challenges facing cancer early detection research.
DFCI and DKFZ join our continuing partners, The University of Manchester, University College London, Knight Cancer Institute at OHSU and the University of Cambridge, in our one-of-a-kind strategic collaboration to revolutionise cancer early detection for real-world patient impact.
Since 2019, ACED has established an extensive research portfolio encompassing biology, technology and trials, with highlights including the BCAN-RAY study to improve risk assessment of breast cancer in young women and the bespoke ACED Training Programme to support the next generation of early detection researchers.
Over the next five years, the Alliance will commit a further £50m in funding to accelerate cutting-edge research in four major programmatic areas – immunology, hereditary cancers, inequalities and interception – each supported by a patient advocacy champion, bringing patients and the public into the heart of cancer early detection research. |
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
Deadline approaching for paediatric cancer initiative |
| C-Further is the new consortium dedicated to advancing therapeutics for children’s and young people’s cancers, jointly set up by Cancer Research Horizons and LifeArc.
We’re calling on the research community to submit projects focused on early-stage therapeutics or validation targets for children’s and young people’s cancers with therapeutic potential.
With a tailored support package, you’ll gain access to cutting-edge drug discovery facilities, expert guidance, funding and a wealth of scientific, technical and commercial resources.
Learn more and submit your research idea by 2 March. |
| | |
|
|
|
| | | | | Despite the growing number of women in life sciences, women remain underrepresented in senior leadership roles.
In recognition of International Day of Women and Girls in Science on 11 February, Infintopes co-founder Lian Ni Lee, Myricx COO Julie Mead, iOnctura CEO Catherine Pickering and Neobe co-founder Annelise Soulier shared their journeys into leadership and how we can better support women in advancing to similar positions.
“We need to encourage and reassure women and girls that science and entrepreneurship are also for them,” said Annelise. | | |
| | | | | | | The workplace has long presented challenges for people with disabilities. While barriers still exist, disability should not prevent anyone from pursuing a successful research career.
A recent Cancer News for Researchers article features four researchers who experience various physical disabilities and learning differences. They share their experiences, highlighting how the right support and adjustments have helped them not just navigate but thrive in their careers.
Continue reading to find out what they’ve found helpful to advancing their career, and ways we could make research inclusive for all. | | |
|
|---|
|
|
|
|
Last few spaces remaining for our clinical research delivery conference |
| Join like-minded clinical research nurses and research delivery staff for our event exploring the challenges and opportunities for cancer clinical research.
The comprehensive agenda is packed with engaging presentations and interactive workshops covering the role of AI in clinical research, patient accessibility, recruitment and retention and designing and delivering inclusive clinical trials for the LGBTIAQ+ community.
Secure your spot at our free event on 26 February. |
| | |
|
|
|
NC3Rs Partnerships and Impact awards announced |
| The NC3Rs Partnerships and Impact awards will accelerate the transfer of 3Rs (replacement, reduction and refinement) models, tools and technologies between labs, building confidence and broadening both capacity and adoption of their use into routine scientific practice.
Helen Wheadon’s team will use the award to adopt an in vitro 3D humanised self-structuring bone model replacing mouse models for certain studies, while also providing technical support and practical training to help other labs at our Scotland Centre incorporate the model.
Richard Houghton will implement a palatable tamoxifen diet for rodents at our Cambridge Institute resulting in better conditions for more than 4,000 mice over the next three years. |
| | |
|
|
|
#ResearchisBeautiful first 2025 pick: out with the old in with the new |
| We’re kicking off the new year with a bang spotlighting January’s outstanding winner of the #ResearchisBeautiful competition.
Hats off to Matthew Bottomley, Clinical Career Development Fellow and Group Lead at CAMS Oxford institute, who submitted our latest winning image. His image depicts a cutaneous squamous cell carcinoma infiltrating into the dermis.
Have a read of our article in Cancer News for Researchers to find out more about Matt, his work, and the story behind his image. |
| | |
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
